| 1 |
34958422 | Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. | 2022 May |
1 |
| 2 |
32880684 | Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. | 2021 Mar |
1 |
| 3 |
33094431 | Detection of pseudoprogression with [18F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. | 2021 Apr |
1 |
| 4 |
33441183 | Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. | 2021 Jan 13 |
2 |
| 5 |
33804417 | Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. | 2021 Mar 1 |
1 |
| 6 |
33879398 | The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. | 2021 Sep |
5 |
| 7 |
34055595 | Additional Value of PET/CT-Based Radiomics to Metabolic Parameters in Diagnosing Lynch Syndrome and Predicting PD1 Expression in Endometrial Carcinoma. | 2021 |
2 |
| 8 |
34370219 | 18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers. | 2021 Nov |
1 |
| 9 |
34552135 | FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy. | 2021 Sep 22 |
1 |
| 10 |
32709713 | Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. | 2020 Jul |
1 |
| 11 |
32801879 | PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT. | 2020 |
1 |
| 12 |
32894535 | Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET. | 2020 Aug |
2 |
| 13 |
31346755 | Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. | 2019 Oct |
1 |